12:00 AM
 | 
Dec 17, 2012
 |  BC Week In Review  |  Company News  |  Deals

Catalent Pharma, UMN Pharma deal

Catalent granted UMN rights to use Catalent's GPEx gene product expression technology to produce cell lines for the development of biosimilars. Under the deal, UMN...

Read the full 104 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >